Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues

#2946

Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.

Aim(s): To evaluate gallstone disease incidence and associated factors in a series of patients treated with long-acting somatostatin analogs for neuroendocrine neoplasms.

Materials and methods: A prospectively-collected database of patients with a diagnosis of neuroendocrine neoplasms, treated with somatostatin analogs at our Institution between 2010 and 2018, was retrospectively analyzed. Patients’ demographics and disease characteristics were analyzed to evaluate the incidence and the factors related to biliary stone disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Qi Z, Zhang Y, Li Y, Shi y, Wang x,

Keywords: neuroendocrine neoplasms, somatostatin analogs, gallstone,